Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.78 |
| ▸ | CTSK | P43235 | 8/20 | 0.72 |
| ▸ | CTSL | P07711 | 6/20 | 0.69 |
| ▸ | CTSB | P07858 | 3/20 | 0.67 |
| ▸ | CTSS | P25774 | 2/20 | 0.67 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27809377 | 1.00 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL9828791 | 1.00 | CAPN1 (0.78) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL2256235 | 0.96 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL2256227 | 0.96 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL2253419 | 0.96 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBCTSS | |
| Carbon Dioxide SCHEMBL2245710 | 0.96 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBCTSS | |
| Carbon Dioxide SCHEMBL2255001 | 0.96 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL2253428 | 0.96 | CAPN1 (0.74) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL6482122 | 0.95 | CAPN1 (0.72) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL14148469 | 0.95 | CAPN1 (0.72) | CAPN1CTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116981681-A | Compounds for the treatment of segmental premature senility syndrome | 普罗基莱弗公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-112972648-A | Application of protease inhibitor in inhibiting novel coronavirus | 珠海诺贝尔国际生物医药研究院有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20190055283-A1 | AZA-PEPTIDE ALDEHYDES AND KETONES | OHIO STATE INNOVATION FOUNDATION | 2019-02-21 | — | — | US | disclosed |
| WO-2015121769-A1 | PROCESS FOR THE PREPARATION OF METHYL N-[(BENZYLOXY)-CARBONYL]-L-LEUCYL-L-PHENYLALANINATE | RANBAXY LABORATORIES LIMITED (IN) | 2015-08-20 | — | — | WO | disclosed |
| CN-102083499-A | Combination therapy of a type II anti-CD20 antibody with a proteasome inhibitor | HOFFMANN LA ROCHE | 2011-06-01 | — | — | CN | disclosed |
| EP-0840614-A1 | CALPAIN INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI WINTHROP, INC. (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1996041638-A1 | CALPAIN INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI WINTHROP, INC. (US) | 1996-12-27 | — | — | WO | disclosed |
| EP-0272671-B1 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD (CH) | 1994-03-16 | — | — | EP | disclosed |
| US-5158936-A | Treating or prevention of tissue damage, inflammation, bone resporpption and muscular dystrophy | SYNTEX (U.S.A.) INC. (US) | 1992-10-27 | — | — | US | disclosed |
| US-5081284-A | N-Oxomethyl-Substituted Peptide | SUNTORY LIMITED (JP) | 1992-01-14 | — | — | US | disclosed |
| US-5055451-A | Prevent tissue damage | SYNTEX INC. (US) | 1991-10-08 | — | — | US | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0272671-A2 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD. (CH) | 1988-06-29 | — | — | EP | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
| US-4564471-A | N-/BENZYLOXYCARBONYL/ASPARTYLPHENYLALANINE | AJINOMOTO CO., INC. (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0027319-B1 | METHOD FOR REDUCTIVE ELIMINATION OF PROTECTING GROUPS AND PREPARATIVE PROCESS USING SUCH METHOD | AJINOMOTO CO., INC. (JP) | 1982-08-11 | — | — | EP | disclosed |
| EP-0027319-A2 | Method for reductive elimination of protecting groups and preparative process using such method | AJINOMOTO CO., INC. (JP) | 1981-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055283-A1 | AZA-PEPTIDE ALDEHYDES AND KETONES | VIP, DNPEP, PEPD | CAPN1 522/4885CTSK 97/4885CTSL 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.